Skip to main content
Log in

Levamisole and leukeamia

  • Guest Editorial
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Chang P, Wiernik PH, Richtenfeld JL, Schiffer CA (1978) Levamisole (L), cytosine arabinoside (Ara-C) and daunorubicin (DNR) induction therapy of adult acute non-lymphocytic leukemia (ANLL). Proc Am Assoc Cancer Res Am Soc Clin Oncol 19:370

    Google Scholar 

  2. Lehtinen M, Ahrenberg P, Hänninen A, Ikkala E, Levanto A, Palva I, Rajamäki A, Roseng»rd S, Saarni M, Selroos O, Timonen T, Waris E, Wasastjerna C, Vuopio P (1978) Levamisole as immunotherapy in acute non-lymphocytic leukaemia. Abstracts (I) XVII Congress of the International Society of Hematology, Paris, p 469

  3. Pavlovsky S, Garay G, Giraudo C, Sackmann F, Hayes A, Svarch E (1978) Grupo Argentino de Tratamiento de la Leucemia Aguda. Chemoimmunotherapy with levamisole in acute lymphocytic leukemia. 69th Annual Meeting of American Association of Cancer Research

  4. Thorling K, Brincker H, Björn Jensen K (1978) Chemoimmunotherapy of acute myeloid leukaemia with levamisole and nine cytostatics. Abstracts (I) XVII Congress of the International Society of Hematology, Paris, p 471

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lehtinen, M. Levamisole and leukeamia. Cancer Immunol Immunother 9, 137 (1980). https://doi.org/10.1007/BF00205616

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00205616

Navigation